Pancreatitis News and Research

RSS

Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.

Immune and metabolic shifts drive acute pancreatitis into chronic disease

Pancreatitis is clinically classified into acute pancreatitis (AP) and chronic pancreatitis (CP). Most patients with AP recover without residual pancreatic dysfunction; a subset develops recurrent AP, and only selected high-risk individuals-particularly those with ongoing etiological exposure, genetic susceptibility, or severe necrotizing disease-progress to CP.

12 Nov 2026

Complex procedure offers relief for children with chronic pancreatitis

Acute recurrent pancreatitis or chronic pancreatitis can take an enormous toll on children, causing severe pain and repeated hospitalizations.

9 Nov 2026

New monoclonal antibody therapy significantly lowers patient triglyceride levels

A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels.

9 Nov 2026

AI tool reads abdominal ultrasounds and accelerates emergency diagnoses

When a patient arrives in the emergency department with severe abdominal pain, every minute counts. Researchers at the University of Colorado Anschutz School of Medicine are investigating ways to streamline the work of radiologists and make it more efficient.

29 Oct 2026

New score predicts thrombosis risk in hospitalized pancreatitis patients

Professor Julia Mayerle and colleagues from LMU University Hospital Munich have developed an admission-based score intended to identify pancreatitis patients more likely to be diagnosed with thrombosis during hospitalization.

28 Oct 2026

Taking a GLP-1 drug? Here's what the safety evidence really shows

A review on GLP-1 receptor agonists highlights risks like pancreatitis and thyroid cancer, emphasizing individual patient risk over general safety concerns.

26 Oct 2026

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

29 Sep 2026

New pre-hospital blood test reduces unnecessary emergency department visits for chest pain

Researchers in The Netherlands have found that about 30% of presentations to emergency departments of patients with chest pain could be avoided if a highly sensitive troponin test is used in combination with other parameters by ambulance crews during pre-hospital triaging.

25 Sep 2026

AI tool provides early warning for organ failure in acute pancreatitis

Acute pancreatitis (AP) is one of the most common acute digestive disorders worldwide, and its most feared complication-persistent organ failure-drives mortality rates of 30% to 50%.

24 Sep 2026

Novel blood test could detect pancreatic cancer at its earliest stages

Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the country, led the development of a new, investigational blood test that could detect pancreatic cancer at its earliest stages, when the disease is more treatable and potentially curable.

16 Sep 2026

Study finds weak evidence for post-hospital alcohol use disorder treatment

A systematic review by researchers at the University of Colorado Anschutz and Yale University found limited evidence that hospital-based interventions can help people with alcohol use disorder connect with outpatient treatment after they leave the hospital.

8 Sep 2026

SHASTA trials show substantial triglyceride reductions with plozasiran

Plozasiran significantly reduced triglyceride levels in severe hypertriglyceridemia patients, showing promise in preventing acute pancreatitis after one year.

31 Aug 2026

Piezo ion channels: Key regulators of digestive health and disease

Mechanosensitive Piezo ion channels, particularly Piezo1 and Piezo2, are gaining recognition as central regulators of digestive system physiology and disease.

7 Aug 2026

Patient-derived organoids uncover new targets for chronic pancreatitis treatment

Around three million people worldwide struggle with chronic pancreatitis, a condition wherein the pancreas becomes inflamed, scarred, and painful.

14 Jul 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Autonomous medical AI outperforms doctors in simulated EHR cases

MIRA, an autonomous AI agent tested in a sandboxed electronic health record, diagnosed 574 real emergency department cases with 88.9% accuracy and outperformed physicians in a matched 311-case comparison. The system ordered tests, generated medication plans, and made admission decisions in simulation, but the authors stress that prospective validation, governance, and physician oversight are still essential.

21 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Chronic pancreatitis care must expand beyond simple pain management

Chronic pancreatitis (CP) diminishes quality-of-life (QoL) across mobility, self-care, daily activities, mental health, and pain-not just abdominal discomfort-according to a new Mayo Clinic study available online on August 27, 2025, and published in Volume 9, Issue 1 of the Journal of Pancreatology on March 30, 2026.

11 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

Modified stem cell therapy reverses new-onset Type 1 diabetes in mice

A group of researchers at the Medical University of South Carolina (MUSC) has recently developed a new stem cell therapy with a remarkable ability to reverse new-onset Type 1 diabetes (T1D) in a mouse model of the disease.

2 Jun 2026